Switch theme
Sign up to access all valuation multiples
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
2006
118
LTM Revenue $7.1M
LTM EBITDA -$260M
$448M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Immunome has a last 12-month revenue (LTM) of $7.1M and a last 12-month EBITDA of -$260M.
In the most recent fiscal year, Immunome achieved revenue of $9.0M and an EBITDA of -$151M.
Immunome expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immunome valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.1M | XXX | $9.0M | XXX | XXX | XXX |
| Gross Profit | $7.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$260M | XXX | -$151M | XXX | XXX | XXX |
| EBITDA Margin | -3684% | XXX | -1674% | XXX | XXX | XXX |
| EBIT | -$260M | XXX | -$153M | XXX | XXX | XXX |
| EBIT Margin | -3687% | XXX | -1697% | XXX | XXX | XXX |
| Net Profit | -$248M | XXX | -$293M | XXX | XXX | XXX |
| Net Margin | -3513% | XXX | -3240% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Immunome's stock price is $9.
Immunome has current market cap of $760M, and EV of $448M.
See Immunome trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $448M | $760M | XXX | XXX | XXX | XXX | $-3.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Immunome has market cap of $760M and EV of $448M.
Immunome's trades at 49.5x EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate Immunome's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immunome has a P/E ratio of -3.1x.
See valuation multiples for Immunome and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $760M | XXX | $760M | XXX | XXX | XXX |
| EV (current) | $448M | XXX | $448M | XXX | XXX | XXX |
| EV/Revenue | 63.5x | XXX | 49.5x | XXX | XXX | XXX |
| EV/EBITDA | -1.7x | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -2.9x | XXX | XXX | XXX |
| EV/Gross Profit | 63.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.1x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | -3.2x | XXX | -2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmunome's last 12 month revenue growth is 26%
Immunome's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.4M for the same period.
Immunome's rule of 40 is -173% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immunome's rule of X is -3618% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Immunome and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | -3684% | XXX | -1674% | XXX | XXX | XXX |
| EBITDA Growth | -26% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -173% | XXX | -1648% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3618% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1433% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1797% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immunome acquired XXX companies to date.
Last acquisition by Immunome was XXXXXXXX, XXXXX XXXXX XXXXXX . Immunome acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Immunome founded? | Immunome was founded in 2006. |
| Where is Immunome headquartered? | Immunome is headquartered in United States of America. |
| How many employees does Immunome have? | As of today, Immunome has 118 employees. |
| Who is the CEO of Immunome? | Immunome's CEO is Dr. Clay B. Siegall,PhD. |
| Is Immunome publicy listed? | Yes, Immunome is a public company listed on NAS. |
| What is the stock symbol of Immunome? | Immunome trades under IMNM ticker. |
| When did Immunome go public? | Immunome went public in 2020. |
| Who are competitors of Immunome? | Similar companies to Immunome include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Immunome? | Immunome's current market cap is $760M |
| What is the current revenue of Immunome? | Immunome's last 12 months revenue is $7.1M. |
| What is the current revenue growth of Immunome? | Immunome revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Immunome? | Current revenue multiple of Immunome is 63.5x. |
| Is Immunome profitable? | Yes, Immunome is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Immunome? | Immunome's last 12 months EBITDA is -$260M. |
| What is Immunome's EBITDA margin? | Immunome's last 12 months EBITDA margin is -3684%. |
| What is the current EV/EBITDA multiple of Immunome? | Current EBITDA multiple of Immunome is -1.7x. |
| What is the current FCF of Immunome? | Immunome's last 12 months FCF is -$142M. |
| What is Immunome's FCF margin? | Immunome's last 12 months FCF margin is -2012%. |
| What is the current EV/FCF multiple of Immunome? | Current FCF multiple of Immunome is -3.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
